Amman: Hikma Pharmaceuticals announced its performance results for the first six months of the current year, ending June 30.
According to Jordan News Agency, the multinational pharmaceutical group said revenues grew by 6% (5% in constant currency) to reach $1.658 billion, compared to $1.569 billion recorded in the first half of last year. The statement added that this growth comes as the group continued to implement its "strategic priorities" during the first half of 2025.
The statement noted the group's operations in the Middle East and North Africa region "performed well" during the same period. During the January-June period, the group expanded its market share and maintained its position as the second-largest pharmaceutical company in terms of sales, with a "growing portfolio and increasing presence in the region."
Hikma CEO Riad Mishlawi said "strategic changes and a renewed focus on growth and innovation began to yield tangible results in the first half of the current year, as the group is witnessing demand." Additionally, the group is strengthening its portfolio, enhancing its manufacturing capabilities, and continuing to "successfully launch new products and sign important strategic partnerships."
During the first half of 2025, he noted the group launched 33 products and submitted 21 files to regulatory authorities across all markets.